Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma AB has appointed Mads Bjerregaard as its new Chief Business Officer, succeeding Jim Knight, who will transition to an advisory role. This strategic move comes as SynAct is at a pivotal stage with its Phase 2b ADVANCE study for rheumatoid arthritis and other indications, aiming to enhance the commercial and partnering prospects of its lead compound, resomelagon. Bjerregaard’s extensive experience in life sciences and international business development is expected to bolster SynAct’s efforts in advancing its innovative treatments and expanding its market presence.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance and overcoming inflammation.
Average Trading Volume: 149,305
Technical Sentiment Signal: Hold
Current Market Cap: SEK942.9M
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.